ATE431156T1 - Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort - Google Patents

Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort

Info

Publication number
ATE431156T1
ATE431156T1 AT05425666T AT05425666T ATE431156T1 AT E431156 T1 ATE431156 T1 AT E431156T1 AT 05425666 T AT05425666 T AT 05425666T AT 05425666 T AT05425666 T AT 05425666T AT E431156 T1 ATE431156 T1 AT E431156T1
Authority
AT
Austria
Prior art keywords
responses
helicobacter pylori
adjuvant
nap
activating protein
Prior art date
Application number
AT05425666T
Other languages
English (en)
Inventor
Prete Gianfranco Del
Elios Mario Milco D
Amedeo Amedei
Andrea Cappon
Bernard Marina De
Original Assignee
Prete Gianfranco Del
Elios Mario Milco D
Amedeo Amedei
Andrea Cappon
Bernard Marina De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prete Gianfranco Del, Elios Mario Milco D, Amedeo Amedei, Andrea Cappon, Bernard Marina De filed Critical Prete Gianfranco Del
Application granted granted Critical
Publication of ATE431156T1 publication Critical patent/ATE431156T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05425666T 2005-09-23 2005-09-23 Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort ATE431156T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05425666A EP1767214B1 (de) 2005-09-23 2005-09-23 Verwendung des Neutrophil-activating-protein von Helicobacter pylori und/oder Teile davon als Adjuvant für die Induktion einer T-helper type 1 (TH1) Immunantwort

Publications (1)

Publication Number Publication Date
ATE431156T1 true ATE431156T1 (de) 2009-05-15

Family

ID=36113801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05425666T ATE431156T1 (de) 2005-09-23 2005-09-23 Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort

Country Status (4)

Country Link
EP (1) EP1767214B1 (de)
AT (1) ATE431156T1 (de)
DE (1) DE602005014481D1 (de)
WO (1) WO2007039451A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
EP3010517B1 (de) * 2013-06-21 2026-04-08 Ondek Pty Ltd Immuntherapiezusammensetzung und verwendung davon
CN110225760B (zh) * 2016-09-15 2023-11-07 埃里西拉医疗公司 T细胞免疫疗法
WO2020156593A1 (zh) * 2019-01-30 2020-08-06 郑州大学 抗特应性皮炎的蛋白
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20240189374A1 (en) 2021-04-23 2024-06-13 Elicera Therapeutics Ab Adenovirus for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1073745B1 (de) * 1998-04-30 2004-12-01 Chiron S.r.l. Verfahren zur immunisierung und behandlung von h. pylori infektion
GB9914960D0 (en) * 1999-06-25 1999-08-25 Chiron Spa Delivery system
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination

Also Published As

Publication number Publication date
EP1767214A1 (de) 2007-03-28
EP1767214B1 (de) 2009-05-13
WO2007039451A1 (en) 2007-04-12
DE602005014481D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
EP4523756A3 (de) Immunotherapeutischer impfstoff und antikörperkombinationstherapie
IS6895A (is) Aðferð til að bera kennsl á, einangra og vinna mótefnavaka við ákveðnum sjúkdómsvaldi
DE60314823D1 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
CR20220578A (es) Anticuerpos de unión a cd3
CY1112572T1 (el) Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
ES2359162T3 (es) Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
SG163598A1 (en) Lawsonia vaccine and methods of use thereof
DE602005014481D1 (de) Verwendung des Neutrophil-activating-protein von Helicobacter pylori und/oder Teile davon als Adjuvant für die Induktion einer T-helper type 1 (TH1) Immunantwort
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
TR201820975A2 (tr) İbuprofen, Psödoefedrin ve Erdostein İçeren Uzatılmış Salım Sağlayan Farmasötik Kompozisyon
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
TW200718783A (en) Novel genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
WO2007107323A8 (en) Novel genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
MY162027A (en) Use of a poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
ATE378351T1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
BRPI0407727A (pt) adjuvante de vacina de linfócito humano
BR0213656A (pt) composição, método para a obtenção de uma resposta imune à tênia, método para vacinar um mamìfero contra tênia, vacina, método para pemitir a vacinação, métodos para a redução de perda sangüìnea, para a redução do tamanho da tênia e para a redução de aflição por tênia em um paciente infectado com tênia, antìgeno recombinante sintético e antìgeno
CN205547608U (zh) 一种用于制鞋的鸟嘴钳
TW200740997A (en) Novel genes and proteins of brachyspira pilosicoli and use of same for diagnosis and therapy
ATE388962T1 (de) Einschlusskörper für die mündliche impfung von tieren
ATE419003T1 (de) Mycobakterielle proteinantigene für krebstherapie und impfung
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties